October 24, 2014 3:28 AM ET


Company Overview of NeuroPhage Pharmaceuticals, Inc.

Company Overview

NeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disaggregating misfolded proteins for the treatment and prevention of chronic neurodegenerative diseases. It also develops therapeutics for the treatment of Alzheimer‘s, Parkinson‘s, and other degenerative diseases. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

222 Third Street

Suite 3120

Cambridge, MA 02142

United States

Founded in 2006





Key Executives for NeuroPhage Pharmaceuticals, Inc.

Co-Founder and Chief Executive Officer
Chairman of Scientific Advisory Board
Scientific Founder and Member of Scientific Advisory Board
Senior Vice President of Preclinical Research and Development
Compensation as of Fiscal Year 2014.

NeuroPhage Pharmaceuticals, Inc. Key Developments

NeuroPhage Pharmaceuticals, Inc. Presents at Biotech Showcase 2014, Jan-14-2014 08:00 AM

NeuroPhage Pharmaceuticals, Inc. Presents at Biotech Showcase 2014, Jan-14-2014 08:00 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: Jonathan Solomon, Co-Founder, Chief Executive Officer, President and Director.

NeuroPhage Pharmaceuticals, Inc. Wins Second Grant from Michael J. Fox Foundation for Parkinson's Disease Research

NeuroPhage Pharmaceuticals, Inc. announced that it has been awarded an $822,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) for its second-generation drug candidate, NPT088, based on NeuroPhage's GAIM (general amyloid interaction motif) platform, which simultaneously targets multiple misfolded proteins central to many neurodegenerative diseases. In particular, the MJFF grant will be applied to research the effect of NPT088 on alpha-synuclein deposits in the brain, a pathological hallmark of Parkinson's disease (PD). This is NeuroPhage's second grant from MJFF applied to the GAIM platform. The proceeds of the new MJFF grant will be used to test the effect of NPT088 on alpha-synuclein accumulation in the brain in a preclinical model of PD. The preclinical study will be conducted in collaboration with Dr. Eliezer Masliah at the University of California, San Diego. NeuroPhage previously demonstrated that a single treatment of NPT001, a first-generation GAIM molecule, produced significant reductions in neuropathology along with improved motor performance in preclinical PD models. NPT088 is in development for the treatment of conditions characterized by multiple misfolded proteins, with initial focus on PD and Alzheimer's disease (AD). Multiple misfolded proteins are often present in such diseases and can increase disease severity and accelerate disease progression.

NeuroPhage Pharmaceuticals, Inc. Names John F. Dee as Chairman and Kenneth A. Buckfire as Director to its Board

NeuroPhage Pharmaceuticals, Inc. announced that current Director John F. Dee has been named Chairman of the Board and Kenneth A. Buckfire has joined as a Director. In connection with the financing, NeuroPhage announced that John F. Dee has been named Chairman and Kenneth A. Buckfire has joined the Board as a Director. Mr. Dee brings a wealth of industry experience as the former CEO of several successful neuroscience-focused biotechnology companies that were acquired by major pharmaceutical firms. Mr. Buckfire brings extensive strategic and financial experience as Vice Chairman of Stifel Investment Banking and President of Miller Buckfire & Company, a Stifel Company.

Similar Private Companies By Industry

Company Name Region
Advanced Photodynamic Technologies, Inc. United States
NeuroVista Corporation United States
ZLB Bioplasma, Inc. United States
Elcelyx Therapeutics, Inc. United States
Intracel Resources, LLC United States

Recent Private Companies Transactions

Private Placement
March 21, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NeuroPhage Pharmaceuticals, Inc., please visit www.neurophage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.